国药现代：拟公开转让控股子公司51%股权

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), is planning to transfer 51% equity of its subsidiary Shanghai Modern Harsen (商丘) Pharmaceutical Co., Ltd. to optimize resource allocation and improve asset operational efficiency [1] Group 1: Company Actions - The company intends to conduct a public transfer of the subsidiary's equity at the Shanghai United Assets and Equity Exchange [1] - The transaction counterpart is currently unspecified, and no transaction contract has been signed yet [1] - The equity transfer is subject to approval from the higher authority, China National Pharmaceutical Group Co., Ltd. [1] Group 2: Financial Performance - For the period from January to April 2025, Shanghai Modern Harsen reported revenue of 101 million yuan and a net loss of 19.898 million yuan [1]